Latest New Zealand Market News

Temple & Webster defied a tough consumer backdrop to post record FY26 revenue of A$665 million and is targeting a substantial 50-80% EBITDA increase in FY27 under new CEO Susie Sugden.

Mangawhai Collective aims to boost its stake in Bremworth from 19.73% to a controlling interest by offering NZD 0.90 per share for nearly 44% of outstanding shares, subject to conditions and shareholder precommitments.

CDL Investments New Zealand reported a modest profit decline for the first half of 2026, reflecting ongoing residential market challenges, while securing a $20 million credit facility to support future development.

Rua Bioscience has gained regulatory approval in New Zealand for five new medicinal cannabis products, setting the stage for domestic sales and advancing its strategy to integrate local cannabis genetics.

FleetPartners has received a non-binding, conditional indicative offer from SG Fleet to acquire all outstanding shares at A$3.601 each, subject to due diligence and regulatory approvals.

Skellerup has raised its FY26 net profit after tax forecast to $64-$65 million, driven by robust demand in the US and New Zealand markets, improved supply chain conditions, and favourable currency and tariff impacts.

Adairs posts 3.7% sales growth in FY26 but underlying EBIT dips 1.3%, weighed down by Focus on Furniture's ongoing struggles and a substantial non-cash impairment.

Summerset Group maintained stable new sales in Q2 2026 with a notable 26% jump in resales, while prudently reducing its New Zealand build rate in response to economic uncertainty.

Kelsian Group has locked in a seven-year NZ$101 million ferry contract in Auckland and is acquiring local operator Belaire Ferries for NZ$8.9 million, marking its first major New Zealand expansion.

Adore Beauty has expanded its debt facilities with Commonwealth Bank, increasing total capacity to $25.2 million to support inventory growth and a new semi-automated distribution centre.

4DMedical has cleared a major regulatory hurdle with the Therapeutic Goods Administration approving its CT:VQ™ lung imaging software, paving the way for commercial use across Australia and strengthening its global footprint.

CleanSpace's AGILE respirator has achieved AS/NZS 17420.2:2021 certification, paving the way for commercialisation in Australia and New Zealand alongside its recent European approval.